EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)

Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study

Giulio Bevilacqua, Dalila Carino, Stefano Salciccia iD, Alessandro Gentilucci, Flavio Forte, Massimiliano Di Marco, Antonio Pastore, Marco Martini, Stefano Signore, Alessandro Calarco, Martino Recchia, Olivia Voglino und 6 weitere

The Prostate · 2026

DOI: 10.1002/pros.70071 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Prostate, 2026. Verfasst von Giulio Bevilacqua und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department Materno Infantile e Scienze Urologiche, University Sapienza, Rome, Italy. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Plant Extracts, Serenoa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic inflammation is commonly observed in benign prostatic hyperplasia (BPH) tissue and may contribute to lower urinary tract symptoms (LUTS) as well as disease progression. This study evaluated the efficacy of combining a standardized extract of Serenoa repens (Sr) with alfuzosin versus alfuzosin monotherapy in men with LUTS due to BPH.

Methods

In this prospective Phase III, randomized, multicenter, real‐world study, 300 treatment‐naïve men with moderate‐to‐severe LUTS (IPSS > 7) and prostate volume > 30 cc were enrolled. Patients received either alfuzosin 10 mg/day or alfuzosin 10 mg plus HESr 320 mg/day for 12 months. Primary endpoints included changes in IPSS and uroflowmetry (Q max ). Secondary endpoints included quality of life (IPSS‐Q8), storage symptoms (IPSS‐Q2 and Q4), nocturia (IPSS‐Q7), erectile function (IIEF‐5), and ejaculatory function (MSHQ‐Ej). Outcomes were analyzed using mixed‐model ANOVA with post hoc Tukey's tests. Statistical analysis was performed using JMP Pro 14 (SAS Institute Inc.). The protocol was approved by our Ethical Committee Lazio Area 1, Protocol 0949/2023, Rif 7385 on December 12, 2023.

Results

Both treatments significantly improved total IPSS over time ( p < 0.0001). Across all time points, combination therapy was associated with consistently lower IPSS scores, demonstrating a significant time‐by‐treatment interaction ( p = 0.007). Nocturia improved significantly over time ( p < 0.0001); the combination group showed greater benefit from Month 3 onward ( p = 0.006), though the main treatment effect was not statistically significant ( p = 0.076). Q max improved in both groups ( p < 0.0001), with a significant time–treatment interaction ( p = 0.006), but no significant main effect of treatment type ( p = 0.113). A mild but significant decline in IIEF‐5 was observed in both groups over time. Treatment adherence exceeded 86% in both arms.

Conclusions

The combination of HESr and alfuzosin was significantly more effective than alfuzosin monotherapy in relieving LUTS, with greater benefits from Month 3 onward. Q max and nocturia also showed greater, although mild, improvements with combination therapy. Sexual function outcomes were comparable between groups. High adherence and real‐world applicability support the clinical value of this combination in managing BPH‐related LUTS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaLower Urinary Tract SymptomsPlant ExtractsSerenoaQuinazolinesMaleHumansAgedMiddle AgedDrug Therapy, CombinationTreatment OutcomeProspective StudiesQuality of LifeUrological AgentsAdrenergic alpha-1 Receptor Antagonists

Stichwörter der Autor:innen

Serenoa repensalfuzosinbenign prostatic hyperplasialower urinary tract symptoms

Substanzen

alfuzosinPlant ExtractsQuinazolinesUrological AgentsAdrenergic alpha-1 Receptor Antagonists

Autor:innen und Institutionen

  • Department Materno Infantile e Scienze Urologiche, University Sapienza, Rome, Italy.
  • Vannini-Figlie San Camillo Hospital, Rome, Italy.
  • Cristo Re Hospital, Rome, Italy.
  • ICOT Hospital, University Sapienza, Rome, Italy.
  • San Filippo Neri Hospital, Rome, Italy.
  • Sant'Eugenio Hospital, Rome, Italy.

ORCID-Profile: Stefano Salciccia, Valenzi Fabio Maria

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Bevilacqua, G., Carino, D., Salciccia, S., Gentilucci, A., Forte, F., Marco, M. D., Pastore, A., Martini, M., Signore, S., Calarco, A., Recchia, M., Voglino, O., Maria, V. F., Viscuso, P., Presicce, F., Shehu, E., Frisenda, M., & Sciarra, A. (2026). Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. The Prostate. https://doi.org/10.1002/pros.70071

Vancouver

Bevilacqua G, Carino D, Salciccia S, Gentilucci A, Forte F, Marco MD, et al. Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. The Prostate. 2026. doi:10.1002/pros.70071

BibTeX
@article{Bevilacqua2026,
  author = {Bevilacqua, Giulio and Carino, Dalila and Salciccia, Stefano and Gentilucci, Alessandro and Forte, Flavio and Marco, Massimiliano Di and Pastore, Antonio and Martini, Marco and Signore, Stefano and Calarco, Alessandro and Recchia, Martino and Voglino, Olivia and Maria, Valenzi Fabio and Viscuso, Pietro and Presicce, Fabrizio and Shehu, Ervin and Frisenda, Marco and Sciarra, Alessandro},
  title = {Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70071}
}
Kostenlos starten →